Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 7.73B |
| Revenue (ttm) | 138.29M |
| Net Income (ttm) | -140.85M |
| Shares Out | 104.53M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | 111.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 575,850 |
| Open | 72.32 |
| Previous Close | 71.67 |
| Day's Range | 71.05 - 74.77 |
| 52-Week Range | 57.92 - 93.66 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 87.92 (+18.9%) |
| Earnings Date | n/a |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Pha...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 87.92, which is an increase of 18.88% from the latest price.
News
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results and hosts a webcast to discuss the year
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and GlaxoSmithKline sign exclusive license agreement for RNAi candidate ARO-HSD against NASH
Earnings Outlook For Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.
Arrowhead Announces JNJ-75220795 in Development for NASH
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen collaborating JNJ-75220795 in Development for NASH
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection at AASLD Liver Meeting
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Presents Clinical Data on ARO-APOC3 for hypertriglyceridemia at AHA 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data on Alpha-1 antitrypsin deficiency at AASLD Liver Meeting
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data on NASH at AASLD Liver Meeting
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results on November 22, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in November 2021 Conferences, AASLD, AHA, Jefferies, Piper Sandler
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Dis...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases and will hold a KOL webinar
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will participate in upcoming October 2021 conferences
Arrowhead Earns $10 Million Phase 1 Milestone Payment
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earned a $10 million milestone from Janssen when RNAi candidate ARO-JNJ1 entered a Phase 1 clinical trial
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Recap: Arrowhead Pharmaceuticals Q3 Earnings
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29...
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal 2021 third quarter results and holds a webcast and conference call
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Al...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial
Arrowhead Pharmaceuticals: Buy the Dip?
This biotech underdog offers more than meets the eye.
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.